Skip to main content
Clinical Trials/KCT0002394
KCT0002394
Recruiting
未知

Prevention of Post-ERCP Pancreatitis by Intraduodenal Indomethacin in ERCP naïve patients: Prospective, Randomized, Placebo-controlled, Double blind, Multicenter Study

Chung-Ang Univerisity Hospital0 sites926 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Chung-Ang Univerisity Hospital
Enrollment
926
Status
Recruiting
Last Updated
7 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
7 years ago
Study Type
Interventional Study
Sex
All

Investigators

Sponsor
Chung-Ang Univerisity Hospital

Eligibility Criteria

Inclusion Criteria

  • 1\) Age \= 20 or age \= 80, 2\) Patients with naïve papilla and first ERCP, 3\) Diagnostic or therapeutic ERCP, 4\) No evidence of significant abnormality in cardiopulmonary function, 5\) No expectation of adverse event after indomethacin application.

Exclusion Criteria

  • 1\) Unwillingness or inability to informed consent for study, 2\) Age \< 20 or \> 80, 3\) Pregnant women, 4\) Lactating women, 5\) Clinical contraindication for ERCP, 6\) History of allergy or hypersensitivity to aspirin or NSAIDs, 7\) Recent history (within 7 days) of NSAIDs medication, 8\) Serum creatinine \> 1\.4 mg/dL, 9\) Active or recent (within 4 weeks) gastrointestinal bleeding, 10\) Active cardiovascular or cerebrovascular disease, 11\) Acute pancreatitis within 72 hours, 12\) Chronic pancreatitis, 13\) ERCP for stent removal or stent change, 14\) Endoscopic sphicterotomy state, 15\) Drug or alcohol abuser, 16\) Psychiatric illness that anticipated inability to follow study protocol.

Outcomes

Primary Outcomes

Not specified

Similar Trials